Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Spedale

Internal Medicine Dothan, AL Medical Doctor

NPI 1699778662 CMS profile 348905

210 Westside Dr, Dothan, AL 36303

Open in the dashboard

General payments

$13,096

606 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Spedale of Dothan, AL is reported in the CMS Open Payments database as having received $13,096 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,570 56
2024 General $1,777 76
2023 General $1,994 92
2022 General $2,406 105
2021 General $2,324 120
2020 General $1,479 91
2019 General $1,546 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Spedale
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anthony Spedale were reported at $1,570. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anthony Spedale Internal Medicine median Middle half National median
2019 $1,546 $159 $48–$570 $163
2020 $1,479 $119 $33–$402 $114
2021 $2,324 $135 $37–$521 $132
2022 $2,406 $141 $42–$496 $149
2023 $1,994 $149 $45–$519 $160
2024 $1,777 $154 $47–$537 $164
2025 $1,570 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,389 90 payments
  2. Janssen Pharmaceuticals, Inc $1,788 66 payments
  3. Amgen Inc. $1,132 60 payments
  4. AstraZeneca Pharmaceuticals LP $1,093 38 payments
  5. Lilly USA, LLC $1,018 59 payments
  6. Amarin Pharma Inc. $663 37 payments
  7. AbbVie, Inc. $618 27 payments
  8. Merck Sharp & Dohme Corporation $606 27 payments
  9. Novartis Pharmaceuticals Corporation $487 28 payments
  10. Pfizer Inc. $373 24 payments
  11. Other $2,930 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,084 605 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $1,464 70 payments
  2. XARELTO $1,412 58 payments
  3. Ozempic $1,218 69 payments
  4. Wegovy $739 13 payments
  5. FARXIGA $699 28 payments
  6. Repatha $497 35 payments
  7. VRAYLAR $484 19 payments
  8. Vascepa $483 32 payments
  9. Otezla $480 27 payments
  10. MOUNJARO $446 20 payments
  11. Other $10,285 538 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 160 drugs

Part D claims

8,174

Median for Internal Medicine: 777

Drug cost

$1,159,433

Median for Internal Medicine: $73,373

Branded share of claims

26.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 168 $199,751
Eliquis Apixaban Brand 133 $145,328
Mounjaro Tirzepatide Brand 100 $125,000
Farxiga Dapagliflozin Propanediol Brand 102 $105,981
Xarelto Rivaroxaban Brand 129 $105,321
Jardiance Empagliflozin Brand 98 $90,512
Trulicity Dulaglutide Brand 56 $61,849
Rybelsus Semaglutide Brand 13 $33,507
Myrbetriq Mirabegron Brand 52 $31,369
Repatha Sureclick Evolocumab Brand 51 $29,912

The 10 drugs with the highest cost, of 160 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$76,395

Of which drugs: $67

Medicare patients

190

Average age 77

Services billed

1,277

98 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 48%
Diabetes 38%
Osteoporosis 23%
Atrial fibrillation 22%
Chronic kidney disease 20%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 32 59 $44
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 42 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $228
$228 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $199
$199 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $135
$135 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
RYBELSUS
  • Novo Nordisk Inc $96
$96 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record